This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of subchondral calcium phosphate (SCP) injections for the treatment of pain and function impairment due to bone marrow lesions (BMLs) associated with knee osteoarthritis (KOA) and/or insufficiency fractures.